This ad listing is expired.
Dengue fever, a potentially fatal, mosquito-borne disease, is spreading rapidly around the world. According to the latest update from the World Health Organization, 2.5 billion people – 40% of the world’s population – live in areas where there is a risk of dengue. The Asia Pacific region is particularly affected as up to 75% of all cases of dengue occur in this part of the world. There is unfortunately no effective drug treatment for dengue and prevention strategies to date have proved ineffective. The only real hope to start defeating this devastating disease is through dengue vaccination campaigns.
Sanofi Pasteur, the vaccines division of Sanofi-Aventis, is developing the world’s first vaccine against dengue. The first clinical trial designed to show the new vaccine’s efficacy has been carried out in Thailand and is due to report later this year.
The company is pleased to invite you to an international media briefing to present the latest information on the global and regional impact of dengue, dengue prevention strategies and an update on the dengue vaccine development. This media briefing takes place during the International Congress on Infectious Diseases (ICID) held in Bangkok.
Speakers: Professor Pratap Singhasivanon, Dean, Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand
Professor Leo Yee Sin, Infectious Disease Clinic, Tan Tock Seng Hospital, Singapore
Dr Jean Lang, R&D Dengue programme leader, Sanofi Pasteur, Lyon, France
Professor Eduardo Massad, Universidade de São Paulo, São Paulo, Brazil
Dr Tapia-Conyer, General Director of Carlos Slim Health Institute, Mexico City, Mexico
Comments